Corbus Pharmaceuticals Holdings, Inc.

CRBP

US21833P3010

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
45.2 ^USD	-6.90%		+5.14%	+648.34%

May. 13	RBC Initiates Corbus Pharmaceuticals Holdings at Outperform With Speculative Risk Qualifier, $77 Price Target	MT
May. 08	Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $60 From $58, Maintains Outperform Rating	MT

Corbus Pharmaceuticals Holdings, Inc Announces Resignation of Barbara White as Chief Medical Officer

September 22, 2021 at 07:53 am EDT

On August 18, 2021, Corbus Pharmaceuticals Holdings, Inc. reported Barbara White’s resignation as Chief Medical Officer.

Latest news about Corbus Pharmaceuticals Holdings, Inc.

RBC Initiates Corbus Pharmaceuticals Holdings at Outperform With Speculative Risk Qualifier, $77 Price Target	May. 13	MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $60 From $58, Maintains Outperform Rating	May. 08	MT
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Certain Restricted Stock Units of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	Apr. 30	CI
Certain Warrants of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	Apr. 30	CI
Certain Options of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	Apr. 30	CI
Certain Common Stock of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	Apr. 30	CI
Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC	Apr. 02	CI
Corbus Pharmaceuticals Files Mixed Shelf	Mar. 13	MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $58 From $51, Maintains Outperform Rating	Mar. 13	MT
Health Care Climbs on Risk Appetite -- Health Care Roundup	Mar. 12	DJ
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12	CI
North American Morning Briefing : Inflation Data -2-	Mar. 12	DJ
North American Morning Briefing : Powell Still in -2-	Mar. 07	DJ
Jefferies Upgrades Corbus Pharmaceuticals Holdings to Buy From Hold	Mar. 06	MT
Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer	Feb. 28	CI
Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024	Feb. 06	CI
Corbus Pharmaceuticals Closes $94.5 Million Public Offering	Feb. 02	MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $51 From $20, Maintains Outperform Rating	Jan. 29	MT
Top Premarket Decliners	Jan. 29	MT
Sector Update: Health Care Stocks Stronger Late Afternoon	Jan. 26	MT
Sector Update: Health Care	Jan. 26	MT
Top Midday Gainers	Jan. 26	MT
Corbus Pharmaceuticals Holdings, Inc. Announces Data from the First-in-Human Clinical Study of CRB-701	Jan. 26	CI

Chart Corbus Pharmaceuticals Holdings, Inc.

Duration

Period

Chart Corbus Pharmaceuticals Holdings, Inc.

More charts

Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFÎ² expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.

Sector

Biotechnology & Medical Research

Calendar

2024-05-31 - American Society of Clinical Oncology Annual Meeting - CRB-701

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

45.2 USD

Average target price

71 USD

Spread / Average Target

+57.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CORBUS PHARMACEUTICALS HOLDINGS, INC.	+648.34%	510M
VERTEX PHARMACEUTICALS INCORPORATED	+8.63%	115B
REGENERON PHARMACEUTICALS, INC.	+13.17%	107B
BIONTECH SE	-12.76%	22.31B
ARGENX SE	-3.99%	21.6B
BEIGENE, LTD.	-7.19%	18.23B
WUXI APPTEC CO., LTD.	-39.93%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+6.67%	14.26B
SAREPTA THERAPEUTICS, INC.	+33.90%	12.37B
LEGEND BIOTECH CORPORATION	-28.60%	8.28B

Bio Therapeutic Drugs